24/7 Market News Snapshot 08 July, 2025 – Oncolytics Biotech, Inc. Common Shares (NASDAQ:ONCY)

July 8, 2025

DENVER, Colo., 08 July, 2025 (www.247marketnews.com) – (NASDAQ:ONCY) are discussed in this article.
Oncolytics Biotech, Inc. (ONCY) is experiencing a notable surge in its stock, opening at $1.03 and reaching a significant increase of 20.79%, currently trading at $1.22. This uptick reflects a closing session price of $1.01, indicative of growing investor confidence and an active market interest, evidenced by a trading volume of 1.77 million shares. Technical analysis suggests a robust bullish trend, prompting market participants to monitor ONCY closely as it may signal ongoing positive advancements within the biotechnology sector.

In conjunction with its stock performance, Oncolytics has made strides in its clinical development of pelareorep, an innovative immunotherapy targeting various cancer types. Recent clinical data illustrates a remarkable two-year survival benefit for patients suffering from first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), with a survival rate of 21.9% compared to a historical benchmark of 9.2%. Findings from studies involving over 100 patients highlight the potential of pelareorep to redefine treatment protocols for difficult cancer indications.

Furthermore, pelareorep is demonstrating promising outcomes in the metastatic breast cancer arena, particularly for patients with HR+/HER2- subtypes. Two randomized Phase 2 studies have revealed an overall survival advantage exceeding ten months relative to standard chemotherapy, with median overall survival rates reaching 21.0 months.

The safety profile of pelareorep is compelling, showing it is well-tolerated among over 1,100 patients, with mild and manageable treatment-related adverse events predominantly consisting of flu-like symptoms. Dr. Thomas Heineman, Chief Medical Officer of Oncolytics, remarked that pelareorep represents a significant innovation in immunotherapy for traditionally “cold” tumors, suggesting that it could enhance immune response in cancers previously deemed unresponsive.

As these favorable results emerge, Oncolytics aims to expedite its clinical initiatives towards registration-enabling studies, leveraging fast-track designations from regulatory bodies, thus enhancing patient access to this potentially transformative therapy. With these advancements, Oncolytics Biotech is strategically positioned to make significant contributions to the oncology field.

Related news for (ONCY)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.